(CATB) To Present CAT-2000 Program of SREBP Modulators for Hyperlipidemias

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that Catabasis will present an overview of the CAT-2000 program, the Company’s product candidate series targeting the Sterol Regulatory Element-Binding Protein, or SREBP, pathway for the potential treatment of hyperlipidemias, at the Kern Lipid Conference. The Kern Lipid Conference will be held August 3 – 5, 2015, in Vail, Colorado at the Vail Marriott Mountain Resort.

• Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, will give a presentation titled “The CAT2000 program: Oral Modulators of SREBP in Development for Hyperlipidemias.” The presentation will take place on Monday, August 3, 2015, at 3:20 pm local time in the Grand Ballroom, Salon F-J.

About CAT-2000

The CAT-2000 series are molecules engineered by Catabasis using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform to inhibit the maturation of Sterol Regulatory Element-Binding Protein (SREBP) and reduce the expression of key proteins involved in LDL-C and triglyceride metabolism. The CAT-2000 series include CAT-2054, CAT-2003, and other conjugates. In the CAT-2000 series, Catabasis’ development priority is CAT-2054 for the treatment of hypercholesterolemia.

About Catabasis

Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company’s SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company’s technology and pipeline of drug candidates, please visit www.catabasis.com.